The Pink Times
Aa
  • Home
  • World News
    • Africa
    • Americas
    • Asia Pacific
    • China
    • Europe
    • India
    • Middle East
    • United Kingdom
    • United States
  • Rights
    • Activism
    • Law
    • Politics
    • Education
    • Media
    • Health
  • Health
  • Culture
    • Art
    • Books
    • Entertainment
    • Drag
    • Fashion
    • History
    • Love
    • People
    • Photography
    • Religion
  • Drag
  • Life
  • Money
  • Tech
  • Sports
  • People
Reading: Study: Bimonthly, injected PrEP better than daily pill at preventing HIV
Share
Aa
The Pink Times
Search
  • Home
  • World News
    • Africa
    • Americas
    • Asia Pacific
    • China
    • Europe
    • India
    • Middle East
    • United Kingdom
    • United States
  • Rights
    • Activism
    • Law
    • Politics
    • Education
    • Media
    • Health
  • Health
  • Culture
    • Art
    • Books
    • Entertainment
    • Drag
    • Fashion
    • History
    • Love
    • People
    • Photography
    • Religion
  • Drag
  • Life
  • Money
  • Tech
  • Sports
  • People
Follow US
The Pink Times > Life > Health > Study: Bimonthly, injected PrEP better than daily pill at preventing HIV
Health

Study: Bimonthly, injected PrEP better than daily pill at preventing HIV

The Pink Times
The Pink Times August 14, 2021
Updated 2021/09/01 at 9:12 PM
Share

When the antiretroviral regimen known as pre-exposure prophylaxis, or PrEP, was launched nearly a decade ago, patients were suddenly able to achieve near-complete protection against contracting HIV by taking just one pill a day.

But there’s a big hitch: Not everyone is equally diligent about sticking to that once-a-day daily pill regimen, and when doses are missed PrEP’s protective shield weakens considerably.

- Advertisement -
Ad imageAd image

But researchers may have solved that issue: A first-of-its-kind injectable PrEP given just once every eight weeks.

A three-year, real-world study has just wrapped up, and the results suggest that when patients are given a single shot of PrEP once every two months, their HIV risk ends up being 66% lower than those who’d been trying to rely on a daily pill.

“The effect difference is largely driven by ‘coverage’ of sex acts,” explained study author Dr. Raphael Landovitz.

In other words, said Landovitz, when a patient doesn’t take their daily PrEP pill as prescribed, “that’s when it ‘fails.'”

But when the same patient gets a long-lasting PrEP shot, they’re essentially guaranteed to have two months of protective medicine in their system to “cover” them if and when they’re intimate with another individual.

Landovitz is a professor of medicine with the University of California, Los Angeles Center for Clinical AIDS Research & Education, and co-director of UCLA’s Center for HIV Identification, Prevention and Treatment Services, or CHIPTS, in Los Angeles.

In the Thursday’s issue of the New England Journal of Medicine, Landovitz and his team reported on their effort to test injectable PrEP’s effectiveness among more than 4,500 patients.

With an average age of 26, roughly 4,000 of the patients were gay or bisexual men; just under 600 were transgender women.

About half were randomly assigned to take a regimen of pills known as Truvada, which entails a specific combination of several antiretroviral drugs. A second pill regimen known as Descovy is also now available.

The remaining patients received a single 600 milligram shot of cabotegravir, a long-acting antiretroviral cocktail.

After being tracked for three years, a total of 52 participants were newly diagnosed with HIV. Of those, 39 were in the pill group, while just 13 were in the injection group.

And Landovitz said solving the “adherence problem” aside, there is another important upside to the injectable option: discretion.

No matter how it’s taken, “PrEP as a concept is empowering,” Landovitz noted, “because it allows someone who may or may not have a say in the decision to have sex, or whether a condom is used, to protect themselves against HIV infection. And for people who — for many reasons — cannot, do not or will not use condoms, PrEP is HIV prevention.”

But shots, he said, are a better means for achieving those ends, because “you don’t have to carry around a pill bottle and risk someone making judgments about why you might be on it, what it might mean, or even cause partners to become upset or violent.”

So when might the injections become available?

Landovitz noted that his team’s approach is now under review at the U.S. Food and Drug Administration, with a decision expected by the end of this year or early 2022.

That would make cabotegravir the first of several versions of injectable PrEP already in the pipeline.

It’s likely to have the added benefit of increasing the pool of at-risk patients who decide to adopt PrEP protection in the first place, said Quarraisha Karim. She’s a professor of epidemiology at Columbia University in New York City, and she authored an accompanying editorial.

In her editorial, Karim characterized the need to stick to a pill regimen as a “major drawback” of the oral form of PrEP, and views an injectable option as being “well suited to persons who are unable to adhere to a daily tablet regimen.”

Which is all to the better because “PrEP coverage needs to increase substantially to achieve the worldwide goal for reducing HIV infection,” she wrote.

“Expanding PrEP options with longer-acting formulations such as injectable cabotegravir is a step in the right direction on the path to ending AIDS as a public health threat,” Karim added.

More informationThere’s more on PrEP at the U.S. Centers for Disease Control and Prevention.

 

Copyright © 2021 HealthDay. All rights reserved.

TAGGED: HIV, HIV-positive, PrEP

Join Us!

Subscribe to our newsletter and never miss our latest news, podcasts and more!
Please wait...

Thank you for sign up!

Zero spam, Unsubscribe at any time.
The Pink Times August 14, 2021
Share this Article
Facebook Twitter Whatsapp Whatsapp LinkedIn Tumblr Reddit VKontakte Telegram Email
Share
https://pbs.twimg.com/profile_images/1433186274085588996/Xt2ihQJl_normal.jpg
@thepinktimes
0 Following
82 Followers
https://pbs.twimg.com/profile_images/1433186274085588996/Xt2ihQJl_normal.jpg Mar 23, 2023
Kate McKinnon makes history again with leading role in sci-fi film #LGBTQrepresentation #IntheBlinkofanEye… https://t.co/ACrLvJLdmO
https://pbs.twimg.com/profile_images/1433186274085588996/Xt2ihQJl_normal.jpg Mar 23, 2023
Step into a world of queer beauty and ancient Greece with photographer Helias Doulis. #QueerGrecoRomance… https://t.co/9kXm7OBXq1
https://pbs.twimg.com/profile_images/1433186274085588996/Xt2ihQJl_normal.jpg Mar 23, 2023
Step inside Elska Magazine's latest issue and discover the hot men of Bern's LGBTQ community. Get ready for intimat… https://t.co/1Y3BS6TkUZ
Out actress Kate McKinnon lands leading role in new sci-fi film
Movies
Stunning Queer Tribute to Ancient Greece’s Male Beauty: A Photographer’s Bold Take
Art Photography
Get up Close and Personal with Bern, Switzerland’s Hot LGBTQ Men in Elska Magazine’s Intimate Portrayal
Photography
Jojo Siwa Reveals Shocking Encounter With Former Employer Over Coming Out as Gay
People
VP Kamala Harris Congratulates Trans TikTok Star Dylan Mulvaney – Bigots React
People
Ad image
Join us!

Subscribe to our newsletter to get our newest articles instantly!

Please wait...

Thank you for sign up!

Most Viewed Posts

  • Hot Photos from Paul’s Book “Larrikin Prince” Unleashed
  • Hot and Sexy: A Visual Exploration of Masculine Bravado and Regal Splendor
  • A Shift in Perspective: The Art of Male Nude Photography
  • A Journey Through Male Body Diversity with InkedKenny and BEEFYBOY
  • The Ginger Sensation of RuPaul’s Drag Race: A Tribute to Bryce Eilenberg

Useful links

About us
Advertise
Contact
Newsletter

The Pink Times
Follow US

All rights reserved

Join Us!

Subscribe to our newsletter and never miss the latest news, podcasts and more!

Please wait...

Thank you for sign up!

Zero spam, Unsubscribe at any time.

Removed from reading list

Undo
Welcome Back!

Sign in to your account

Lost your password?